Ernexa Therapeutics Reports $4M Net Loss for Q2 2026, Cash Balance Increases to $5M

Ernexa Therapeutics Inc. reported a net loss of $4.0 million for the three months ended June 30, 2026, compared to a loss of $3.1 million for the same period in 2025. For the six months ended June 30, 2026, the company recorded a net loss of $9.5 million, a decrease from a loss of $11.3 million in the prior year. The increase in losses was primarily attributed to a $2.0 million non-cash impairment charge related to goodwill, which was fully impaired as of March 31, 2026. Total operating expenses for the second quarter of 2026 were $4.1 million, up from $2.5 million in the same quarter of 2025, driven mainly by increased research and development costs.

In terms of financial position, Ernexa's cash balance rose to approximately $5.0 million as of June 30, 2026, compared to $1.9 million at the end of 2025. The company utilized $6.4 million in cash for operating activities during the first half of 2026, reflecting a significant increase in operational expenditures. The company has been actively raising capital, having secured approximately $9.5 million in net proceeds from a public offering in February 2026, and has also initiated an At-the-Market (ATM) program to raise additional funds.

Strategically, Ernexa has made significant advancements in its product development pipeline, particularly with its lead candidate, ERNA-101, which is being developed for platinum-resistant ovarian cancer. The company has collaborated with the University of Texas MD Anderson Cancer Center to conduct preclinical studies, which have shown promising results in tumor reduction and survival rates. Additionally, Ernexa has been accepted into a global acceleration program in Japan, aimed at facilitating market entry and collaboration opportunities.

Operationally, the company has undergone changes in its leadership structure, with Sanjeev Luther serving as the interim principal financial officer following the resignation of the previous finance executive. Furthermore, Ernexa has expanded its board of directors, appointing David Polinsky as a new member. The company is also actively seeking strategic partnerships and research grants to bolster its development efforts and financial resources.

Looking ahead, Ernexa anticipates continued operational losses as it progresses through its development programs. The company plans to complete its Investigational New Drug (IND) enabling studies and submit its IND application in 2026, with the goal of entering a Phase I clinical trial later in the year. However, the company has acknowledged the need for additional capital to support its operations and may need to adjust its spending if cash resources become insufficient.